Medicine and Dentistry
Patient
100%
Hepatocellular Carcinoma
48%
Therapeutic Procedure
45%
Chronic Hepatitis C
25%
Development
18%
Chronic Hepatitis B
17%
Combination Therapy
16%
Liver Cirrhosis
16%
Hepatitis B Virus
15%
Hepatitis C Virus
15%
Antivirus Agent
15%
Incidence
15%
Antiviral Therapy
14%
Inpatient
14%
Age
13%
Ribavirin
12%
Chronic Kidney Disease
12%
Entecavir
11%
Tenofovir Alafenamide
11%
Human Immunodeficiency Virus
10%
Genotype
9%
Telaprevir
9%
Hazard Ratio
9%
Analysis
9%
Fibrosis
8%
Peginterferon
8%
Follow up
8%
Liver
8%
Hepatitis B Antigen
8%
Interferon
7%
Tenofovir Disoproxil
7%
Person
7%
Hepatitis B
7%
Hepatitis C
6%
Diagnosis
6%
Predictor
6%
Immune Reconstitution Inflammatory Syndrome
6%
Sofosbuvir
6%
Serum
5%
Infection
5%
Adverse Event
5%
Insulin Resistance
5%
Antiretroviral Therapy
5%
Focused Ion Beam
5%
Man
5%
Computer Assisted Tomography
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Hepatitis C
37%
Liver Cell Carcinoma
36%
Ribavirin
35%
Telaprevir
32%
Liver Cirrhosis
26%
Hepatitis C Virus
26%
Antivirus Agent
19%
Adverse Event
18%
Peginterferon
15%
Fibrosis
14%
Hepatitis B Virus
14%
Chronic Hepatitis B
14%
Infection
12%
Sofosbuvir
11%
Interferon
10%
Anemia
9%
Hepatitis C
9%
Incidence
9%
Entecavir
8%
Simeprevir
8%
Hepatitis B
8%
Virus RNA
7%
Tenofovir Disoproxil
7%
Interleukin 28B
6%
Hepatitis C Virus Subtype 1b
6%
Thrombocytopenia
6%
Tenofovir Alafenamide
6%
Hepatitis C Virus Genotype 1
6%
Relapse
5%
Chronic Kidney Failure
5%
Deterioration
5%
Hepatitis B Surface Antigen
5%
RNA
5%
Nursing and Health Professions
Patient
49%
Chronic Hepatitis C
19%
Ribavirin
17%
Combination Therapy
16%
Telaprevir
12%
Liver Cirrhosis
11%
Peginterferon
9%
Incidence
8%
Hepatitis C
7%
Interleukin 28B
7%
Procedures
7%
Sofosbuvir
7%
Inpatient
7%
Antivirus Agent
6%
Antiviral Therapy
6%
Adverse Event
5%
Chronic Hepatitis B
5%